Other substances

Albuterol

beta-adrenergic receptor agonist 

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
1
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2
Preprint 		human renal cortical epithelial cells Apr/23/2020

AI-suggested references

Link Publication date
Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence
Nov/30/2021
Nebulized in-line endotracheal dornase alpha and albuterol administered to mechanically ventilated COVID-19 patients: a case series.
Sep/29/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04681079 Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19 Completed May/04/2021 Jan/18/2022
  • Alternative id - 0192
  • Interventions - Drug: albuterol sulfate (MDI)|Drug: albuterol sulfate (nebulizer)
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Theravance Biopharma Investigational Site, Kansas City, Kansas, United States
  • Study designs - Observational Model: Other|Time Perspective: Other
  • Enrollment - 14
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Viral Load
Export (.csv)